Genmab — August 2020

[Helge_LarsenPI-redaktør]

Beløbet vil være mindre end standardkurtagen for at handle en enkelt Genmab aktie.

[Skyggen]

Helge Jeg er også klar på et Support Abonnement.

[Helge_LarsenPI-redaktør]

God morgen.

[Plimsoller]

God morgen

[Mogan]

God morgen -:)

[Helge_LarsenPI-redaktør]

Tak Skygge.

[SEACOP]

Donation. Så vel fortjent.

[E_L]

Home Infusion of Thyroid Eye Disease Treatment Shows Efficacy of Home Care During Pandemic https://www.pharmacytimes.com/news/home-infusion-of-thyroid-eye-disease-treatment-shows-efficacy-of-home-care-during-pandemic

[E_L]

“In the wake of the COVID-19 outbreak, access to home infusion therapy is more important than ever,” -Soon to be followed by Ofatumumab and, who knows, maybe even Dara SC

[bibob]

Yes, it would be nice.

[Helge_LarsenPI-redaktør]

Tak Seacop.

[Helge_LarsenPI-redaktør]

Servicemeddelelse: Tjek MARKED ud i topmenuen. Der er nye værktøjer til dig.

[Klarussen]

E.L.: det er fantastisk godt nyt for patienterne, men vel ikke noget som øger Genmabs indtjening?

[E_L]

Genmab will receive royalties on Tepezza sales. If the patient can't get to the hospital, or does not want to go to a hospotal due to Covid, treatment may be delayed or skipped. With home infusion you can still sell Tepezza to him at home.

[E_L]

this will be the same for Ofatumumab; the first B-cell therapy that can be self-administered at home using an autoinjector pen. It is one of the reasons Covid could potentially create a competitive advantage for Ofa (besides the difference in
B cell depletion)

[E_L]

as for Dara, we heard JNJ is training nurses for home administration (-even though Jan said a while back that he did not expect that to happen; the current situation may have changed things)

[E_L]

AbbVie cans Voyager Alzheimer’s, Parkinson’s gene therapy pacts https://www.fiercebiotech.com/biotech/abbvie-cans-voyager-alzheimer-s-parkinson-s-gene-therapy-pacts

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[bikube]

Så er Dara Sub.q. godkendt i Canada.

[E_L]

New trial to compare maintenance therapy with Daratumumab or Lenalidomide https://www.clinicaltrials.gov/ct2/show/NCT04497961?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Duobody+OR+Teprotumumab+OR+Tepezza+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+Teclistamab+OR+Talquetamab+OR+Amivantamab&lupd_s=08%2F04%2F2020&draw=2&rank=2